XML 20 R4.htm IDEA: XBRL DOCUMENT v3.8.0.1
Condensed Consolidated Statement of Operations and Comprehensive Loss - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2017
Sep. 30, 2016
Sep. 30, 2017
Sep. 30, 2016
Income Statement [Abstract]        
Collaboration revenue [1] $ 2,387 $ 1,549 $ 8,672 $ 2,820
Operating expenses:        
Research and development [2] 17,845 12,052 49,770 26,666
General and administrative 8,112 4,107 24,522 18,974
Total operating expenses 25,957 16,159 74,292 45,640
Loss from operations (23,570) (14,610) (65,620) (42,820)
Other (expense) income:        
Interest expense   (1)   (8,051)
Loss from equity method investment (359)   (1,310) (686)
Gain on extinguishment of convertible loan       11,482
Other expense, net (71) (75) (238) (141)
Total other (expense) income, net (430) (76) (1,548) 2,604
Net loss before income taxes (24,000) (14,686) (67,168) (40,216)
Provision for income taxes (707) (8) (1,330) (84)
Net loss (24,707) (14,694) (68,498) (40,300)
Foreign currency translation adjustment 8 (1) 38 (18)
Comprehensive loss (24,699) (14,695) (68,460) (40,318)
Reconciliation of net loss to net loss attributable to common shareholders:        
Net loss (24,707) (14,694) (68,498) (40,300)
Loss attributable to noncontrolling interest   14   24
Net loss attributable to common shareholders $ (24,707) $ (14,680) $ (68,498) $ (40,276)
Net loss per share attributable to common shareholders—basic and diluted $ (0.62) $ (2.77) $ (1.72) $ (7.43)
Weighted-average common shares outstanding used in net loss per share attributable to common shareholders—basic and diluted 40,088,718 5,292,348 39,904,863 5,422,617
[1] Including the following revenue from a related party, see Note 11:
[2] Including the following research and development expense with a related party, See Note 11: